Ionis Pharmaceuticals, Inc.
42.93USD
-0.9800 (-2.23%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on IONS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.93▼ | -$0.81 | 1 | 5 |
| Next quarter | -$0.89▼ | -$0.64 | 1 | 1 |
| Current year | -$2.62▼ | -$2.62 | 3 | 0 |
| Next year | -$1.15▼ | -$1.07 | 3 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.88 | -$0.42 | +0.45 (+51.7%) |
| 2026-03-31 | -$0.78 | -$0.3 | +0.47 (+60.9%) |
| 2025-12-31 | -$1.22 | -$1.15 | +0.07 (+5.6%) |
| 2025-09-30 | -$1.05 | -$0.61 | +0.44 (+41.8%) |
273 ratings from 32 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| BMO Capital | Upgraded from Market Perform | Outperform | $54 $66 | Oct 22, 2026 |
| UBS | Upgraded from Neutral | Buy | $46 $88 | Oct 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Sep 24, 2026 |
| JP Morgan | Maintained | Overweight | $76 $70 | Sep 22, 2026 |
| Guggenheim | Maintained | Buy | $89 $80 | Sep 15, 2026 |
| Barclays | Maintained | Overweight | $90 $85 | Sep 9, 2026 |
| Morgan Stanley | Maintained | Overweight | $110 $104 | Sep 8, 2026 |
| Goldman Sachs | Maintained | Neutral | $69 $56 | Sep 8, 2026 |
| BMO Capital | Maintained | Market Perform | $61 $54 | Sep 8, 2026 |
| Canaccord Genuity | Maintained | Buy | $95 $85 | Sep 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115 $100 | Sep 8, 2026 |
| Needham | Reiterated | Buy | $86 | Sep 4, 2026 |
| BMO Capital | Maintained | Market Perform | $60 $61 | Sep 4, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $115 | Sep 4, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $115 | Aug 31, 2026 |
| BMO Capital | Initiated from Outperform | Market Perform | $60 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $72 $76 | Aug 3, 2026 |
| Wells Fargo | Maintained | Overweight | $100 $95 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $125 $115 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $106 $89 | Jul 21, 2026 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $100 $85 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $130 $125 | Jul 10, 2026 |
| Morgan Stanley | Maintained | Overweight | $130 $110 | Jul 10, 2026 |
| Barclays | Maintained | Overweight | $115 $90 | Jul 10, 2026 |
160 filings from 26 insiders · 16 buy / 18 sell over 6m
Officers and directors of IONS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Devers Shannon L.Officer, EVP, Chief Human Resources Ofc | Sell | 1.4k | $43.54 | $59k | Oct 16, 2026 |
| Swayze EricOfficer, EVP Research | Sellindirect | 53 | $43.54 | $2k | Oct 16, 2026 |
| Devers Shannon L.Officer, EVP, Chief Human Resources Ofc | ExerciseRestricted Stock Unit | 2.8k | — | — | Oct 15, 2026 |
| Devers Shannon L.Officer, EVP, Chief Human Resources Ofc | Exercise | 2.8k | — | — | Oct 15, 2026 |
| Swayze EricOfficer, EVP Research | ExerciseindirectRestricted Stock Unit | 125 | — | — | Oct 15, 2026 |
| Swayze EricOfficer, EVP Research | Exerciseindirect | 125 | — | — | Oct 15, 2026 |
| BENNETT C FRANKOfficer, EVP, Chief Scientific Officer | Other | 110 | $51.31 | $6k | Aug 31, 2026 |
| O'NEIL PATRICK R.Officer, EVP CLO & General Counsel | Other | 63 | $51.31 | $3k | Aug 31, 2026 |
| Monia Brett PDirector; Officer, Chief Executive Officer | Other | 98 | $51.31 | $5k | Aug 31, 2026 |
| Birchler BrianOfficer, EVP, Corp and Development Ops | Other | 58 | $51.31 | $3k | Aug 31, 2026 |
| HAYDEN MICHAEL REUBENDirector | Buyindirect | 20.0k | $51.60 | $1.06M | Jul 31, 2026 |
| BERTHELSEN SPENCER RDirector | Other | 5.2k | — | — | Jul 15, 2026 |
| HERMAN JOAN EDirector | Other | 5.2k | — | — | Jul 15, 2026 |
| DIAZ ALLENE M.Director | Exercise | 10.1k | $47.11 | $476k | Jul 7, 2026 |
| KORDASIEWICZ HOLLY BOfficer | Sell | 362 | $84.30 | $31k | Jul 7, 2026 |
| DIAZ ALLENE M.Director | Sell | 10.1k | $85.42 | $864k | Jul 7, 2026 |
| BENNETT C FRANKOfficer | Sell | 20.5k | $83.58 | $1.74M | Jul 7, 2026 |
| KLEIN JOSEPH S IIIDirector | Exercise | 11.5k | $39.94 | $460k | Jul 1, 2026 |
| KLEIN JOSEPH S IIIDirector | Sell | 11.5k | $79.04 | $910k | Jul 1, 2026 |
| BAROLDI JOSEPHOfficer | Exerciseindirect | 5.6k | $32.60 | $277k | Jun 26, 2026 |
No analyst notes on IONS yet.
Analyst Ratings
23 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 9 | 12 | 4 | 0 | 0 | Buy1.80 |
| 1 mo ago | 9 | 10 | 5 | 0 | 0 | Buy1.83 |
| 2 mo ago | 9 | 10 | 5 | 0 | 0 | Buy1.83 |
| 3 mo ago | 9 | 10 | 4 | 0 | 0 | Buy1.78 |
Members whose judged calls on IONS have played out most reliably.
No settled calls on IONS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice